Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
3
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
microbiome
3
×
national
national blog main
national top stories
new york blog main
new york top stories
novartis
pfizer
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
3
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
astrazeneca
bristol-myers squibb
cancer
clinical trials
diagnostics
eli lilly
finch therapeutics
hepatitis b
What
bio
3
×
roundup
drug
acquisitions
advantages
august
bar
biggest
biotech
brings
build
busy
buy
ceo
company’s
daniel
days
debut
decisions
devices
drugs
dyne’s
expect
fda
gamble
gilead
legacy
market
medco’s
microbiome
mover
moves
new
news
nods
openly
opioid
o’day
past
patients
Language
unset
Current search:
microbiome
×
" san francisco blog main "
×
bio
×
amgen
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More